Oxidative stress and apoptosis: A new treatment paradigm in cancer

Frontiers in Bioscience

Volumn 11, Issue 1 P.1-446, 2006, Pages 300-312

  Engel, Ryan H ^a   Evens, Andrew M ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Apoptosis; Cancer; Glutathione; Oxidative Stress; Reactive Oxygen Species; Review

Indexed keywords

EID: 27744557065     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/1798     Document Type: Review

References (114)

1. Dalton WS: Targeting the mitochondria: an exciting new approach to myeloma therapy. Clin Cancer Res 8, 3643-3645 (2002)
2. Brookes PS, A.L. Levonen, S. Shiva, P. Sarti, V.M. Darley-Usmar: Mitochondria: regulators of signal transduction by reactive oxygen and nitrogen species. Free Radic Biol Med 33, 755-764 (2002)
3. Smith PG, F. Wang , K.N. Wilkinson, K. Savage, U. Klein, D. Neuberg, G. Bollag, M. Shipp, R.C Aguiar: The phosphodiesterase PDE4B limits cAMP-associated PI3K/AKT-dependent apoptosis in diffuse large B-cell lymphoma. Blood 105, 308-16 (2005)
4. Dvorakova K, C.N. Waltmire, C.M. Payne, M.E. Tome, M.M. Briehl, R.T. Dorr. Induction of mitochondrial changes in myeloma cells by imexon. Blood 97, 3544-3551 (2001)
5. Byrd JC, S. Kitada, I.W. Flinn, J.L. Aron, M. Pearson, D. Lucas, J. Reed: The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood 99, 1038-1043 (2002)
6. th ed, 14-20 (2005)
7. Toyokuni S: Reactive oxygen species-induced molecular damage and its application in pathology. Pathol Iny 49, 91-102, (1999)
8. Gromer S, S. Urig, K. Becker: The thioredoxin system-from science to clinic. Med Res Rev 24, 40-89 (2004)
9. Cerutti PA: Prooxidant states and tumor promotion. Science 227, 375-381 (1985)
10. Jing Y, J. Dai, R.M. Chalmers-Redman, W.G. Tatton, S. Waxman:Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood 94, 2102-2111 (1999)
11. Chen Q, Y.C. Chai, S. Mazumder, C. Jiang, R.M. Macklis, G.M. Chisolm, A. Almasan: The late increase in intracellular free radical oxygen species during apoptosis is associated with cytochrome c release, caspase activation, and mitochondrial dysfunction. Cell Death Differ 10, 323-334 (2003)
12. Li PF, R. Dietz, R. Von Harsdorf: p53 regulates mitochondrial membrane potential through reactive oxygen species and induces cytochrome c-independent apoptosis blocked by Bcl-2. Embo J 18, 6027-6036 (1999)
13. Usgui-Fukai M, R.W. Alexander: Reactive oxygen species as mediators of angiogenesis signaling: role of NAD(P)H oxidase. Mol Cell Biochem 264 (1-2), 85-87 (Sep 2004)
14. Berneis K, M. Kofler, W. Bollag, A. Kaiser, A. Langeman: The degradation of deoxyribonucleic acid by new tumour inhibiting compounds: the intermediate formation of hydrogen peroxide. Experientia 19, 132-133 (1963)
15. Berneis K, W. Bollag, M. Kofler and H. Luthy: The enhancement of the after effect of ionizing radiation by a cytotoxic methylhydrazine derivative. Eur J Cancer 21, 43-49 (1966)
16. Martz G, A. D'Alessandri, H.J. Keel, W. Bollag: Preliminary clinical results with a new antitumor agent RO 4-6467 (NSC 77213). Cancer Chemother Rep 33, 5-14 (1963)
17. Mathe G, O. Schweisguth, M. Schneider, J.L Amiel, L. Berumen, G. Brule, A. Cattan, L. Schwarzenberg: Methylhydrazine in treatment of Hodgkin's disease and various forms of hematosarcoma and leukemia. Lancet 12, 1077-1080 (1963)
18. Kurosu T, T. Fukuda, T. Miki, O. Miura: BCL6 overexpression prevents increase in reactive oxygen species and inhibits apoptosis induced by chemotherapeutic reagents in B-cell lymphoma cells. Oncogene 22(29), 4459-68 (2003)
19. Muller I, D. Niethammer, G. Bruchelt: Anthracycline-derived chemotherapeutics in apoptosis and free radical cytotoxicity. Int J Mol Med 1(2), 491-4 (1998 Feb)
20. Mahmutoglu I, H. Kappus: Oxy radical formation during redox cycling of the bleomycin-iron (III) complex by NADPH-cytochrome P-450 reductase. Biochem Pharmacol 34(17), 3091-4 (1985 Sep)
21. Williamson JM, B. Boettcher, A. Meister: Intracellular cysteine delivery system that protects against toxicity by promoting glutathione synthesis. Proc Natl Acad Sci U S A 79(20), 6246-9 (1982)
22. Meister A: Glutathione metabolism and its selective modification. J Biol Chem 263, 17205-17208 (1988)
23. Sun J, Y. Chen, M. Li, Z. Ge: Role of antioxidant enzymes on ionizing radiation resistance. Free Radic Biol Med 24, 586-593 (1998)
24. Kidd, P: Glutathione: Systemic Protectant Against Oxidative and Free Radical Damage. Alt Med Review 2 (3), 155-176 (1997)
25. Powis G, W.R. Montfort: Properties and biological activities of thioredoxins. Annu Rev Pharmacol Toxicol 41, 261-295 (2001)
26. Nathan CF, B.A. Arrick, H.W. Murray, N.M. DeSantis, Z.A. Cohn: Tumor cell anti-oxidant defenses. Inhibition of the glutathione redox cycle enhances macrophage-mediated cytolysis. J Exp Med 153, 766-82 (1981)
27. Arrick BA, C.F. Nathan, O.W. Griffith, Z.A. Cohn: Glutathione depletion sensitizes tumor cells to oxidative cytolysis. J Biol Chem 257, 1231-37 (1982)
28. Arrick BA, C.F. Nathan: Glutathione as a determinant of therapeutic efficacy: a review. Cancer Res 44, 4224-32 (1984)
29. Griffith OW, A. Meister: Potent and specific inhibition of glutathione synthesis by buthionine sulfoximine. J Biol Chem 254, 7558-60 (1979)
30. Bailey HH: L-S, R-buthionine sulfoximine: historical development and clinical issues. Chem Biol Interact 111-112, 239-54 (1998)
31. Dorr RT, J.D. Liddil, M.J. Soble: Cytotoxic effects of glutathione synthesis inhibition by L-buthionine-(SR)-sulfoximine on human and murine tumor cells. Invest New Drugs 4, 305-13 (1986)
32. Gartenhaus RB, S.N. Prachand, M. Paniaqua, Y. Li, L.I. Gordon: Arsenic trioxide cytotoxicity in steroid and chemotherapy-resistant myeloma cell lines. Clin Cancer Res 8(2), 566-72 (2002 Feb)
33. Kitamura K, Y. Minami, K. Yamamoto, Y. Akao, H. Kiyoi, H. Saito, T. Naoe: Involvement of CD95-independent caspases 8 activation in arsenic trioxide-induced apoptosis. Leukemia 14, 1743-50 (2000)
34. Miyajima A, J. Nakashima, K. Yoshioka, M. Tachibana, H. Tazaki, M. Murai: Role of reactive oxygen species in cis-dichlorodiammineplatinum-induced cytotoxicity on bladder cancer cells. Br J Cancer 76(2), 206-210 (1997)
35. Rudin CM, Z. Yang, L.M. Schumaker, D.J. VanderWeele, K. Newkirk, M.J. Egorin, E.G. Zuhowski, K.J. Cullen: Inhibition of glutathione synthesis reverses Bcl-2-mediated cisplatin resistance. Cancer Res 63(2), 312-318 (2003)
36. Skapek SX, O.M. Colvin, O.W. Griffith, G.B. Elion, D.D. Bigner, H.S. Friedman: Enhanced melphalan cytotoxicity following buthionine sulfoximine-mediated glutathione depletion in a human medulloblastoma xenograft in athymic mice. Cancer Res 48 (10), 2764-2767 (1988)
37. Bahlis, N: Feasibility and Correlates of Arsenic Trioxide Combined with Ascorbic Acid-mediated Depletion of Intracellular Glutathione for the Treatment of Relapsed/Refractory Multiple Myeloma. Clinical Cancer Research, Vol 8 3658-3668 (Dec 2002)
38. Dai J, R.S. Weinberg, S. Waxman, Y. Jing: Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood 93, 268-77 (1999)
39. Chen GQ, J. Zhu, X.G. Shi, J.H. Ni, H.J. Zhong, G.Y. Si, X.L. Jin, W. Tang, X.S. Li, S.M. Xong, Z.X. Shen, G.L. Sun, J. Ma, P. Zhang, T.D. Zhang, C. Gazin, T. Naoe, S.J. Chen, Z.Y. Wang, Z. Chen: In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood 88, 1052-61 (1996)
40. Grad JM, N.J. Bahlis, I. Reis, M.M. Oshiro, W.S. Dalton, L.H. Boise: Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells. Blood 98, 805-13 (2001)
41. Klassen, CD: Heavy metals and heavy-metal antagonists. In: Goodman & Gilman's The Pharmacological Basis of Therapeutics. Eds: JG Hardman LE Limbird McGraw Hill, NY 1649-72 (1996)
42. Soignet SL, S. Frankel, M. Tallman: Arsenic trioxide (ATO) in relapsed acute promyelocytic leukemia (APL): the combined results and follow-up from the U.S. pilot and multicenter trials. Blood 96 (suppl, pt 1 of 2), 827a (2000)
43. Niu C, H. Yan, T. Yu H.P. Sun, J.X. Liu, X.S. Li, W. Wu, F.Q. Zhang, Y. Chen, L. Zhou, J.M. Li, X.Y. Zeng, R. Yang, M.M. Yuan, M.Y. Ren, F.Y. Gu, Q. Cao, B.W. Gu, X.Y. Su, G.Q. Chen, S.M. Xiong, T.D. Zhang, S. Waxman, Z.Y. Wang, Z. Chen, J. Hu, Z.X. Shen, S.J. Chen: Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 94, 3315-24 (1999)
44. Munshi N, R. Desikan, M. Zangari: Marked antitumor effect of arsenic trioxide (As2O3) in high-risk refractory multiple myeloma. Blood 94 (suppl 1), 123a (1999)
45. Ochi T, T. Kaise, Y. Oya-Ohta: Glutathione plays different roles in the induction of the cytotoxic effects of inorganic and organic arsenic compounds in cultured BALB/c 3T3 cells. Experientia 50, 115-20 (1994)
46. Scott N, K.M. Hatlelid, N.E. MacKenzie, D.E. Carter: Reactions of arsenic (III) and arsenic (V) species and glutathione. Chem Res Toxicol 6, 102-6 (1993)
47. Jing Y, J. Dai, R.M. Chalmers-Redman, W.G. Tatton, S. Waxman: Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood 94, 2102-11 (1999)
48. Schuliga M, S. Chouchane , E.T. Snow: Upregulation of glutathione-related genes and enzyme activities in cultured human cells by sublethal concentrations of inorganic arsenic. Toxicol Sci 70, 183-92 (2002)
49. Karasawas N, J.M. Carcamo, G. Stratis, D.W. Golde: Vitamin C protects HL60 and U266 cells from arsenic toxicity. Blood 105(10), 4004-12 (2005)
50. Zhu XH, Y.L Shen, Y.K Jing, X. Cai, P. M. Jia, Y. Huang, W. Tang, G. Y. Shi, Y. P. Sun, J. Dai, Z. Y. Wang, S. J. Chen, T. D. Zhang: Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide in clinically achievable concentrations. J Natl Cancer Inst 91, 772-8 (1999)
51. Rousselot P, S. Labaume, J.P. Marolleau J. Larghero, M. H. Noguera, J. C. Brouet, J. P. Fermand: Arsenic trioxide and melarsoprol induce apoptosis in plasma cell lines and in plasma cells from myeloma patients. Cancer Res 59, 1041-48 (1999)
52. Park WH, J.G. Seol, E.S. Kim, J. M. Hyun, C. W. Jung, C. C. Lee, B. K. Kim, Y. Y. Lee: Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis. Cancer Res 60, 3065-71 (2000)
53. Deaglio S, D. Cannell, G. Baj G, A. Arnulfo, S. Waxman, F. Malavasi: Evidence of an immunologic mechanism behind the therapeutical effects of arsenic trioxide (As2O3) on myeloma cells. Leuk Res 25, 227-35 (2001)
54. Shen ZX, G.Q. Chen, J.H. Ni, X. S. Li, S. M. Xiong, Q. Y. Qiu, J. Zhu, W. Tang, G. L. Sun, K. Q. Yang, Y. Chen, L. Zhou, Z. W. Fang, Y. T. Wang, J. Ma, P. Zhang, T. D. Zhang, S. J. Chen, Z. Chen, Z. Y. Wang: Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in elapsed patients. Blood 89, 3354-60 (1997)
55. Zheng Y, H. Yamaguchi, C Tian, M. W. Lee, H. Tang, H.G. Wang, Q. Chen: Arsenic trioxide induces apoptosis through activation of Bax in hematopoietic cells. Oncogene 24(20), 3339-47 (2005)
56. Perkins C, C.N. Kim, G. Fang, K.N. Bhalla: Arsenic induces apoptosis of multidrug -resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR,MRP, Bcl-2 or Bcl-c(L). Blood 95(3), 1014-22 (2000)
57. Dvorakova K, C. Payne, M.E. Tome, M. M. Briehl, T. McClure, R. T. Dorr: Induction of oxidative stress and apoptosis in myeloma cells by the aziridine-containing agent imexon. Biochem Pharmacol 60, 749-58 (2000)
58. Mead JR, R.A. Burger, J.D. Morrey, R. P. Warren, K. M. Okleberry, R. W. Sidwell: Effect of immunomodulators in the hu-PBL-SCID mouse model. Biotechnol Ther 4, 133-43 (1993)
59. Funk CY, J. Eisman, E.M. Hersh: Treatment of the murine, retrovirus-induced lymphoproliferative immunodeficiency disease (LP-BM5) in C57BL/10 mice with the immunomodulator Imexon. AIDS Res Hum Retroviruses 8, 633-8 (1992)
60. Hersh EM, C.R. Gschwind, C.W. Taylor, R. T. Dorr, R. Taetle, S. E. Salmon: Antiproliferative and antitumor activity of the 2-cyanoaziridine compound Imexon on tumor cell lines and fresh tumor cells in vitro. J Natl Cancer Inst 84, 1238-44 (1992)
61. Marchetti P, D. Decaudin, A. Macho, N. Zamzami, T. Hirsch, S. A. Susin, G. Kroeme T: Redox regulation of apoptosis: Impact of thiol oxidation status on mitochondrial function. Eur J Immunol 27, 289-96 (1997)
62. Sato M, M. Sasaki, T. Oguro T, Y. Kuroiwa, T. Yoshida: Induction of metallothionein synthesis by glutathione depletion after trans- and cis-stilbene oxide administration in rats. Chem Biol Interact 98, 15-25 (1995)
63. Cai X, Y.L. Shen, X. Zhu, P. M. Jia, Y. Yu, L. Zhou, Y. Huang, J. W. Zhang, S. M. Xiong, S. J. Chen, Z. Y. Wang, Z. Chen, G. Q. Chen: Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia. Leukemia 14, 262-70 (2000)
64. Sordet O, C. Rebe, I. Leroy I, J. M. Bruey, C. Garrido, C. Miguet, G. Lizard, S. Plenchette, L. Corcos, E. Solary: Mithochondria-targeting drugs arsenic trioxide and lonidamine bypass the resistance of TPA-differentiated leukemic cells to apoptosis. Blood 97, 3931-40 (2001)
65. Dorr RT, J.D Liddil, M.K. Klein, E.M. Hersh: Preclinical pharmacokinetics and antitumor activity of Imexon. Invest New Drugs 13, 113-6 (1995)
66. Evens AM, S. Prachand, B. Shi B, M. Paniaqua, L.I. Gordon, R.B. Gartenhaus: Imexon-induced apoptosis in multiple myeloma tumor cells is caspase-8 dependent. Clin Cancer Res 10, 1481-1491 (2004)
67. M Micksche, EM Kokoschka, P Sagaster, U Bicker: Phase I study for a new immunostimulating drug, BM 06 002, in man. In: Immune Modulation and Control of Neoplasia by Adjuvant Therapy. Ed. Chirigos MA, Raven Press, NY, 403-13 (1978).
68. Salmon SE, E.M. Hersh: Sensitivity of multiple myeloma to imexon in the human in the human tumor cloning assay. J Natl Cancer Inst 86, 228-30 (1994)
69. Sagaster P, E.M. Kokoschka, O. Kokran, M, Micksche: Antitumor activity of Imexon. J Natl Cancer Inst 87, 935-36 (1995)
70. Sessler JL, R.A. Miller: Texaphyrins: new drugs with diverse clinical applications in radiation and photodynamic therapy. Biochem Pharmacol 59, 733-739 (2000)
71. Magda D, N. Gerasimchuk, P. Lecane, R.A. Miller, J.E. Biaglow, J.L. Sessler: Motexafin gadolinium reacts with ascorbate to produce reactive oxygen species. Chem Commun (Camb) 22, 2730-2731 (2002)
72. Xu S, K. Zakian, H. Thaler, C. Matei, A. Alfieri, Y. Chen, J. A. Koutcher: Effects of Motexafin gadolinium on tumor metabolism and radiation sensitivity. Int J Radiat Oncol Biol Phys 49, 1381-1390 (2001)
73. Magda D, C. Lepp, N. Gerasimchuk, I. Lee, J. L. Sessler, A. Lin, J. E. Biaglow, R. A. Miller: Redox cycling by motexafin gadolinium enhances cellular response to ionizing radiation by forming reactive oxygen species. Int J Radiat Oncol Biol Phys 51, 1025-1036 (2001)
74. Woodburn KW. Intracellular localization of the radiation enhancer motexafin gadolinium using interferometric Fourier fluorescence microscopy. J Pharmacol Exp Ther 297, 888-894 (2001)
75. Miller RA, K. Woodburn, Q. Fan, M.F. Renschler, J.L. Sessler, J.A. Koutcher: In vivo animal studies with gadolinium (III) texaphyrin as a radiation enhancer. Int J Radiat Oncol Biol Phys 45, 981-989 (1999)
76. Young SW, F. Qing, A. Harriman, J. L. Sessler, W. C. Dow, T. D. Mody, G. W. Hemmi, Y. Hao, R. A. Miller: Gadolinium(III) texaphyrin: a tumor selective radiation sensitizer that is detectable by MRI. Proc Natl Acad Sci US A 93, 6610-6615 (1996)
77. Donnelly ET, Y. Liu, Y.O. Fatunmbi, I. Lee, D. Magda, S. Rockwell: Effects of texaphyrins on the oxygenation of EMT6 mouse mammary tumors. Int J Radiat Oncol Biol Phys 58, 1570-1576 (2004)
78. Miller RA, K.W. Woodburn, Q. Fan, I. Lee, D. Miles, G. Duran, B. Sikic, D. Magda: Motexafin gadolinium: a redox active drug that enhances the efficacy of bleomycin and doxorubicin. Clin Cancer Res 7, 215-3221 (2001)
79. Miller RA, I. Lee, D. Magda: Motexafin gadolinium (MGd) increases tumor response to chemotherapy in Lewis lung cancer (LLC) animal model, in American Society of Clinical Oncology proceedings (ASCO) 21:117a (2002)
80. Lepp C QF, P. Lecane, D. Magda, R. Miller: Motexafin gadolinium (MGd) enhances the activity of cisplatin, carboplatin, and docetaxel. Conf Proc of AACR (2004)
81. Evens AM, P. Lecane, D. Magda, S. Prachand, S. Singhal: Motexafin gadolinium generates reactive oxygen species and induces apoptosis in sensitive and highly resistant multiple myeloma cells. Blood 105, 1265-1273 (2005)
82. O'Dwyer PJ, T.C. Hamilton, P.P. LaCreta, J. M. Gallo, D. Kilpatrick, T. Halbherr, J. Brennan, M. A. Bookman, J. Hoffman, R. C. Young, R. L. Comis, R. F. Ozols: Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer. J Clin Oncol 14(1), 49-56 (1996 Jan)
83. Bailey HH, G. Ripple, K.D. Tutsch, R. Z. Arzoomanian, D. Alberti, C. Feierabend, D. Mahvi, J. Schink, M. Pomplun, R. T. Mulcahy, G. Wilding: Phase I study of continuous-infusion L-S,R-buthionine sulfoximine with intravenous melphalan. J Natl Cancer Inst 89(23), 1789-96 (1997 Dec)
84. Dorr, R: Phase I clinical trial of imexon. JCO, ASCO Annual Meeting Proceedings, Vol 22 (14S) 3181 (2004 July 15
85. Lazo G: Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: the M.D. Anderson experience. Cancer 97(9), 2218-2224 (2003 May)
86. Soignet SL, P. Maslak, Z.G. Wang, S. Jhanwar, S.E. Calleja, L. J. Dardashti, D. Corso, A. DeBlasio, J. Gabrilove, D. A. Scheinberg, P. P. Pandolfi, R. P., Jr. Warrell: Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 339, 1341-8 (1998)
87. Soignet SL, S.R Frankel, D. Douer, Tallman, M. S. H. Kantarjian, E. Calleja, R. M. Stone, M. Kalaycio, D. A. Scheinberg, P. Steinherz, E. L. Sievers, S. Coutre, S. Dahlberg, R. Ellison, R. P., Jr. Warrell: United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 19, 3852-3860 (2001)
88. Soignet S, S.R. Frankel, M.S. Tallman: U.S. multicenter trial of arsenic trioxide (AT) in acute promyelocytic leukemia (APL). Blood 94(suppl 1), 698a (1999)
89. Huang CH, W.J. Chen, C.C. Wu, Y. C. Chen, Y. T. Lee: Complete atrioventricular block after arsenic trioxide treatment in an acute promyelocytic leukemia patent. Pacing Clin Electrophysiol 22, 965-7 (1999)
90. Ohnishi K, H. Yoshida, K. Shigeno, S. Nakamura, S.S. Fujisawa, K. Naito, K. Shinjo, Y. Fujita, H. Matsui, A. Takeshita, S. Sugiyama, H. Satoh, H. Terada, R. Ohno: Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia. Ann Intern Med 133, 881-5 (2000)
91. Unnikrishnan D, J.P. Dutcher, N. Varxhneya, R. Lucariello, M. Api, S. Garl, P. H. Wiernik, S. Chiaramida: Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide. Blood 97, 1514-6 (2001)
92. Beckman KJ, J.L. Bauman, P.A. Pimental, C. Garrard, R. J. Hariman: Arsenic-induced torsade de pointes. Crit Care Med 19, 290-2 (1991)
93. Goldsmith S, A.H. From: Arsenic-induced atypical ventricular tachycardia. N Engl J Med 303, 1096-8 (1980)
94. Westervelt P, R.A. Brown, D.R. Adkins, H. Khoury, P. Curtin, D. Hurd, S. M. Luger, M. K. Ma, T. J. Ley, J. F. DiPersio: Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide. Blood 98, 266-71 (2001)
95. Borrow J, A.D. Goddard, D. Sheer, E. Solomon: Molecular analysis of acute promyelocytic leukemia breakpoint cluster region on chromosome 17. Science 249, 1577-80 (1990)
96. Camacho LH, S.L. Soignet, S. Chanel, R. Ho, G. Heller, D. A. Scheinberg, R. Ellison, Warrell, R. P., Jr.: Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide. J Clin Oncol 18, 262-5 (2000)
97. Shen ZX, Z.S. Zhan: All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA 101(15), 5328-35 (2004 April 13)
98. Munshi, N: Clinical activity of arsenic trioxide for the treatment of multiple myeloma. Leukemia 16, 1835-1837 (2002)
99. Hussein, M. M. Saleh, F. Ravandi, J. Mason, R.M. Rifkin, R. Ellison: Phase 2 study of arsenic trioxide in patients with relapsed of refractory multiple myeloma. British Journal of Haematology 125, 470-476 (2004)
100. Evens AM, M.S. Tallman, R.B. Gartenhaus: The potential of arsenic trioxide in the treatment of malignant disease: past, present, and future. Leuk Res (9), 891-900 (2004 Sep 28)
101. Wang TS, Y.F. Shu, Y.C. Liu, K. Y. Jan, H. Huang: Glutathione peroxidase and catalase modulate the genotoxicity of arsenite. Toxicology 121, 229-37 (1997)
102. Berenson JR, R.A. Swift, D. Ferretti, M. B. Purner: A prospective, open-label safety and efficacy study of combination treatment with melphalan, arsenic trioxide, and ascorbic acid in patients with relapsed or refractory multiple myeloma. Clin Lymphoma 5(2), 130-4 (2004 Sep)
103. Rosenthal DI, P. Nurenberg, C.R. Becerra, E. P. Frenkel, D. P. Carbone, B. L. Lum, R. Miller, J. Engel, S. Young, D. Miles: A phase I single-dose trial of gadolinium texaphyrin (Gd-Tex), a tumor selective radiation sensitizer detectable by magnetic resonance imaging. Clin Cancer Res 5, 739-745 (1999)
104. Carde P, R. Timmerman, M.P. Mehta, C. D. Koprowski, J. Ford, R. B. Tishler, D. Miles, R. A. Miller, M. F. Renschler: Multicenter phase Ib/II trial of the radiation enhancer motexafin gadolinium in patients with brain mteastases. J Clin Oncol 19, 2074-2083 (2004)
105. Mehta MP, W.R. Shapiro, M.J. Glantz, R. A. Patchell, M. A. Weitzner, C. A. Meyers, C. J. Schultz, W. H. Roa, M. Leibenhaut, J. Ford, W. Curran, S. Phan, J. A. Smith, R. A. Miller, M. F. Renschler: Lead-in phase to randomized trial of motexafin gadolinium and whole-brain radiation for patients with brain metastases: centralized assessment of magnetic resonance imaging, neurocognitive, and neurologic end points. J Clin Oncol 20, 3445-3453 (2002)
106. Mehta MP, P. Rodrigus, C.H. Terhaard, A. Rao, J. Suh, W. Roa, L. Souhami, A. Bezjak, M. Leibenhaut, R. Komaki, C. Schultz, R. Timmerman, W. Curran, J. Smith, S. C. Phan, R. A. Miller, M. F. Renschler: Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J Clin Oncol 21, 2529-2536 (2003)
107. Meyers CA, J.A. Smith, A. Bezjak M. P. Mehta, J. Liebmann, T. Illidge, I. Kunkler, J. M. Caudrelier, P. D. Eisenberg, J. Meerwaldt, R. Siemers, C. Carrie, L. E. Gaspar, W. Curran, S. C. Phan, R. A. Miller, M. F. Renschler: Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial. J Clin Oncol 22, 157-165 (2004)
108. Lin TS, L. Naumovski, P. Lecane, M.S. Lucas, M.E. Moran, A.P. Mone, D.M. Lucas, S. Phan, R.A. Miller, J.C. Byrd: Effects of the Redox Mediator Motexafin Gadolinium in a Pilot Phase I Trial in Refractory Chronic Lymphocytic Leukemia. American Society of Hematology (ASH). San Diego, CA (2004)
109. th International Symposium and Expert Workshops on Leukemia and Lymphoma, Amsterdam, Netherlands, (2005 Mar)
110. Bellosillo B, N. Villamor, A. Lopez-Guillermo, S. Marce, J. Esteve, E. Campo, D. Colomer, E. Montserrat: Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species. Blood 98, 2771-7 (2001)
111. Pei XY, Y. Dai, S. Grant: Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin Cancer Res 10, 3839-52 (2004)
112. Fribley A, Q. Zeng, C.Y. Wang: Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells. Mol Cell Biol 24, 9695-704 (2004)
113. Ungerstedt JS, Y. Sowa, W.S. Xu, Y. Shao, M. Dokmanovic, G. Perez, L. Ngo, A. Holmgren, X. Jiang, P. A. Marks: Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci U S A 102, 673-8 (2005)
114. Shanafelt TD, Y.K Lee, N.D. Bone, A. K. Strege, V. L. Narayanan, E. A. Sausville, S. M. Geyer, S. H. Kaufmann, N. E. Kay: Adaphostin-induced apoptosis in CLL B cells is associated with induction of oxidative stress and exhibits synergy with fludarabine. Blood 105, 2099-2106 (2005)